IDRSF News and Press, Idorsia Ltd Registered Shares From 08/28/25

Allschwil, Switzerland – August 28, 2025 Idorsia Ltd (SIX: IDIA) releases an OnDemand investor webcast outlining how TRYVIO™ (aprocitentan) – the first and only hypertension therapy targeting the endothelin pathway – fits into the treatment landscape for di...

2025-07-30 18:32:21 ET Idorsia Ltd (IDRSF) Q2 2025 Earnings Conference Call July 30 2025, 08:00 AM ET Company Participants Andrew Jones - Senior VP, Head of Corporate Communications & Investor Relations Arno Groenewoud - Executive VP & CFO Michael Moye - ...

2025-07-30 10:46:59 ET More on Idorsia Historical earnings data for Idorsia Financial information for Idorsia Read the full article on Seeking Alpha For further details see: Idorsia GAAP EPS of -0.06 CHF, revenue of 72M CHF

Aprocitentan, on top of background therapy, showed clinically meaningful and durable blood pressure (BP) reduction and a decrease in proteinuria in Black patients with confirmed resistant hypertension Allschwil, Switzerland – April 9, 2025 Idorsia Ltd (SIX: IDIA) today announce...

Allschwil, Switzerland – April 9, 2025 Idorsia Ltd (SIX: IDIA) today announced that the US Food & Drug Administration (FDA), after having released TRYVIO from its REMS (Risk Evaluation and Mitigation Strategy) requirement ( announced on March 17, 2025 ), has now approved the up...

2025-03-04 10:59:51 ET Idorsia Ltd (IDRSF) Q4 2024 Earnings Conference Call March 04, 2025 08:00 AM ET Company Participants Andrew Jones - Senior Vice President, Head of Corporate Communications & Investor Relations Andre Muller - Chief Executive Officer Benj...